The use of 131I in doses of several mCi for scans can stun the thyrocytes and thyroid cancer
cells, whereas the usual dose (300 μCi) of 123I does not. We compared the diagnostic …

Detection of residual tissue after thyroidectomy for papillary or follicular thyroid carcinoma
may be performed using diagnostic imaging with either 123I or 131I. The former is often …

PURPOSE: To determine if stunning can be seen with a 185-MBq (5-mCi) dose of iodine
131 (131I) at diagnostic whole-body scanning and, if stunning is seen, determine if there is …

" Thyroid stunning" from diagnostic iodine-131 imaging prior to ablative therapy with 131 I for
well-differentiated thyroid carcinoma has been well reported, but documentation of the effect …

We performed a prospective random study to assess possible thyroid stunning by a 185-
MBq iodine-131 dose used to diagnose thyroid remnants. Patients with differentiated thyroid …

Purpose Iodine-123 is a pure gamma emitter and has excellent characteristics for imaging
with modern scintillation cameras. The goal of this study was to compare the performance of …

Background In the management of patients with differentiated thyroid carcinoma, direct
comparison of the presence of scintigraphic stunning after a diagnostic dose of 131 I with …

Thyroid stunning is usually defined as decreased uptake or trapping of radioiodine 131I by
normal thyroid tissue or differentiated thyroid cancer after diagnostic administration of 131I …

Recent publications described many discrepant findings about thyroid “stunning” after the
administration of 131I diagnostic activities to patients with differentiated thyroid carcinoma …

M ETHODS Patients were prepared for scanning by withdrawal from thyroxine for 41 ±12
days and/or from 13 for 20 ±7 days. Lowiodinediets, diuretics, or TSH injections were not …